Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943982103> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2943982103 endingPage "13S" @default.
- W2943982103 startingPage "13S" @default.
- W2943982103 abstract "INTRODUCTION: A recent phase II trial demonstrated that high-dose erythropoietin with therapeutic hypothermia for hypoxic-ischemic encephalopathy (HIE) results in decreased brain injury on MRI and improved 1-year motor function in comparison to treatment with therapeutic hypothermia alone. We sought to investigate whether such an intervention is cost-effective in cases of moderate and severe HIE. METHODS: A TreeAge decision analytic model was designed comparing erythropoietin vs. no erythropoietin in a cohort of 10,000 term neonates with moderate and severe HIE. Rates of global brain injury and neurodevelopmental disability (NDD) were derived from a phase II trial investigating high-dose erythropoietin and hypothermia for HIE, and rates of NDD due to global brain injury were estimated from existing literature. Costs were derived from prior literature. Utilities were applied to discounted life expectancy to generate quality-adjusted life years (QALYs). All costs and QALYs were discounted at an annual rate of 3% with cost-effectiveness threshold of $100,000 per QALY. Sensitivity analyses were conducted to assess the robustness of these results. RESULTS: High-dose erythropoietin for the management of moderate and severe HIE resulted in lower costs and higher QALYs compared to therapeutic hypothermia alone. In our theoretical cohort, utilizing high-dose erythropoietin results in 3,900 fewer cases of major NDD. In a univariate sensitivity analysis, when varying the cost of erythropoietin, erythropoietin was found to be cost-effective across all ranges considered. CONCLUSION: Erythropoietin therapy with therapeutic hypothermia is a cost-effective intervention resulting in improved outcomes for neonates with hypoxic-ischemic encephalopathy." @default.
- W2943982103 created "2019-05-16" @default.
- W2943982103 creator A5006906657 @default.
- W2943982103 creator A5020508020 @default.
- W2943982103 creator A5043560058 @default.
- W2943982103 creator A5055173625 @default.
- W2943982103 date "2019-05-01" @default.
- W2943982103 modified "2023-09-25" @default.
- W2943982103 title "The Use of Erythropoietin in Hypoxic-Ischemic Encephalopathy: A Cost-Effectiveness Analysis [12A]" @default.
- W2943982103 doi "https://doi.org/10.1097/01.aog.0000559359.42463.93" @default.
- W2943982103 hasPublicationYear "2019" @default.
- W2943982103 type Work @default.
- W2943982103 sameAs 2943982103 @default.
- W2943982103 citedByCount "0" @default.
- W2943982103 crossrefType "journal-article" @default.
- W2943982103 hasAuthorship W2943982103A5006906657 @default.
- W2943982103 hasAuthorship W2943982103A5020508020 @default.
- W2943982103 hasAuthorship W2943982103A5043560058 @default.
- W2943982103 hasAuthorship W2943982103A5055173625 @default.
- W2943982103 hasConcept C112930515 @default.
- W2943982103 hasConcept C126322002 @default.
- W2943982103 hasConcept C177713679 @default.
- W2943982103 hasConcept C187212893 @default.
- W2943982103 hasConcept C2776164570 @default.
- W2943982103 hasConcept C2777390192 @default.
- W2943982103 hasConcept C2778534260 @default.
- W2943982103 hasConcept C2778621155 @default.
- W2943982103 hasConcept C2909832856 @default.
- W2943982103 hasConcept C3019080777 @default.
- W2943982103 hasConcept C42219234 @default.
- W2943982103 hasConcept C64332521 @default.
- W2943982103 hasConcept C71924100 @default.
- W2943982103 hasConcept C72563966 @default.
- W2943982103 hasConceptScore W2943982103C112930515 @default.
- W2943982103 hasConceptScore W2943982103C126322002 @default.
- W2943982103 hasConceptScore W2943982103C177713679 @default.
- W2943982103 hasConceptScore W2943982103C187212893 @default.
- W2943982103 hasConceptScore W2943982103C2776164570 @default.
- W2943982103 hasConceptScore W2943982103C2777390192 @default.
- W2943982103 hasConceptScore W2943982103C2778534260 @default.
- W2943982103 hasConceptScore W2943982103C2778621155 @default.
- W2943982103 hasConceptScore W2943982103C2909832856 @default.
- W2943982103 hasConceptScore W2943982103C3019080777 @default.
- W2943982103 hasConceptScore W2943982103C42219234 @default.
- W2943982103 hasConceptScore W2943982103C64332521 @default.
- W2943982103 hasConceptScore W2943982103C71924100 @default.
- W2943982103 hasConceptScore W2943982103C72563966 @default.
- W2943982103 hasIssue "1" @default.
- W2943982103 hasLocation W29439821031 @default.
- W2943982103 hasOpenAccess W2943982103 @default.
- W2943982103 hasPrimaryLocation W29439821031 @default.
- W2943982103 hasRelatedWork W1985602048 @default.
- W2943982103 hasRelatedWork W2033237312 @default.
- W2943982103 hasRelatedWork W2043480430 @default.
- W2943982103 hasRelatedWork W2242308574 @default.
- W2943982103 hasRelatedWork W2765518338 @default.
- W2943982103 hasRelatedWork W2943982103 @default.
- W2943982103 hasRelatedWork W3008453445 @default.
- W2943982103 hasRelatedWork W4248421597 @default.
- W2943982103 hasRelatedWork W4292537211 @default.
- W2943982103 hasRelatedWork W4310955238 @default.
- W2943982103 hasVolume "133" @default.
- W2943982103 isParatext "false" @default.
- W2943982103 isRetracted "false" @default.
- W2943982103 magId "2943982103" @default.
- W2943982103 workType "article" @default.